MORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial ...

MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year ...

Syneos Health cemented a multi-year deal to use Microsoft’s platform for deploying artificial intelligence (AI) in its clinical trials and commercial programs. The agreement announced this week ...

MORRISVILLE – Syneos Health is making a lot of news today with its financial report topping Wall Street expectations and Wednesday evening’s announcement that it is acquiring Synteract, which also has ...

(Reuters) -Syneos Health Inc is making a new effort to sell itself after a reduced backlog of contracts for providing clinical research to drug developers led to a 52% plunge in its shares over the ...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Syneos ...

It’s not entirely clear which party emerged victorious after a recent arbitration hearing involving Syneos Health and FSD Pharma, as both sides are claiming vindication. Syneos Health offers clinical ...

Syneos Health inked a multiyear deal with Microsoft to further develop a platform that leverages machine learning to support and speed the analysis, design and operations of clinical trials and ...

MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today ...

Shareholders might have noticed that Syneos Health, Inc. (NASDAQ:SYNH) filed its third-quarter result this time last week. The early response was not positive, with shares down 8.4% to US$53.08 in the ...

Syneos Health helps drug companies develop and sell their drugs; the projects often take multiple quarters to complete. One possibility is that Syneos and the SEC disagree on how much revenue from the ...